Correlation between BCRP Expression and Efficacy of Neoadjuvant Chemotherapy
-
摘要: 目的 探讨原发性乳腺癌组织中乳腺癌耐药蛋白(breast cancer resistance protein,BCRP)的表达与新辅助化疗疗效的相关性。方法 采用免疫组织化学MaxVisionTM一步法检测84例原发性乳腺癌组织中BCRP的表达,结合新辅助化疗后临床疗效及术后病理组织学Miller&Payne(MP)分级,分析BCRP的表达与新辅助化疗疗效及相关病理指标的相互关系。结果 (1)原发性乳腺癌组织中BCRP的阳性表达率为71.43%。(2)BCRP的表达水平与新辅助化疗临床疗效有关,新辅助化疗后获得cCR组患者BCRP表达水平明显低于SD+PD组和cPR组,三组间BCRP表达水平的差异有统计学意义(χ2=9.779,P=0.008)。(3)BCRP的表达水平与新辅助化疗后组织学反应有关,组织学显著反应组(病理反应4~5级)BCRP的表达水平明显低于组织学非显著反应组(病理反应1~3级),差异有统计学意义(χ2=8.649,P=0.003)。(4)BCRP的表达水平与新辅助化疗后残余阳性腋窝淋巴结的个数正相关(r =0.518,P=0.000)。结论 BCRP在原发性乳腺癌组织中有一定程度的表达,BCRP的表达水平可以预测新辅助化疗的临床疗效及组织学反应,BCRP的表达水平与新辅助化疗后残余阳性腋窝淋巴结的个数正相关,BCRP可以作为判断患者化疗效果及预后指标之一。Abstract: Objective To analyze the correlation between the expression of breast cancer resistance protein (BCRP) and effi cacy of neoadjuvant chemotherapy. Methods BCRP expression in 84 patients of primary breast cancer were investigated by MaxVisionTM one step before chemotherapy. Then the efficacy of neoadjuvant chemotherapy and pathological changes of post-chemotherapy surgical specimens was compared. The correlation between the expression of BCRP and efficacy of neoadjuvant chemotherapy was analyzed. Results (1)The positive expression rate of BCRP was 71.43% in patients with primary breast cancer. (2) BCRP expression was associated with the clinical effi cacy of neoadjuvant chemotherapy. BCRP level in patients with acquired cCR after neoadjuvant chemotherapy was lower than that in SD+PD group and cPR group. BCRP expression between the three groups were signifi cantly different (χ2=9.779,P=0.008). (3)BCRP expression was associated with the pathological response after neoadjuvant chemotherapy. BCRP expression in group of major histological response(grade of 4-5) was signifi cantly lower than that in group of non major histological response (grade of 1-3)(χ2=8.649,P=0.003). (4)There was signifi cant positive relevance between BCRP expression and the number of axillary lymph node metastases( r =0.518, P=0.000). Conclusion BCRP expression in primary breast carcinoma tissue could predict the clinical effi cacy of neoadjuvant chemotherapy and histology effects. There is signifi cantly positive relevance between the expression of BCRP and the number of axillary lymph node metastases. BCRP could be index for effi cacy and prognosis judgement after neoadjuvant chemotherapy.
-
Key words:
- Breast cancer /
- Breast cancer resistance protein /
- Neoadjuvant chemotherapy /
- Efficacy
-
-
[1] Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells[J]. Proc Natl Acad Sci U S A, 1998,95(26):15665-70. [2] Rocchi E, Khodjakov A, Volk EL, et al. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane[J]. Biochem Biophys Res Commum,2000, 27 1(1):42-6. [3] Ni Z, Bikadi Z, Rosenberg MF, et al. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2) [J]. Curr Drug Metab,2010,11(7): 603-17. [4] Chen YX, Li LH, Yang XL, et al. Expressions of CK5, CK8 and BCRP in the lesions of mammary gland and its significance[J]. Zhong Liu,2010,30(6):510-4.[陈颖欣,李连宏,杨晓丽,等. CK5、 CK8和BCRP在人乳腺病变组织中的表达及其意义[J].肿瘤, 20 10,30(6):510-4.] [5] Zhang Q, Tan XJ, Zheng GP, et al. Correlation between the expression of breast cancer resistance protein BCRP and chemotherapy drugs sensitivity[J].Zhongguo Yi Yao Ke Xue, 20 12,2(11):12-3,18.[张琼,谭小军,郑国沛,等. 乳腺癌耐药蛋 白BCRP表达与化疗药物敏感性的关系[J]. 中国医药科学, 20 12,2(11):12-3,18.] [6] van den Heuvel-Eibrink MM,van der Holt B,Burnett AK, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age[J].Ann Hematol.2007,86(5):329-37. [7] Zhang CN, Liu XQ, Han Y, et al. Reveral effects of pulsed magnetic fields on breast cancer cell line MCF-7/ADR in vitro and in vivo[J]. Zhongguo Zhong Liu Lin Chuang,2008,35 (21) :1241-3.[ 张翠宁,刘晓秋,韩英,等.脉冲磁场逆转乳腺 癌细胞多药耐药性的作用研究[J].中国肿瘤临床,2008,35 (21) :1241-3.] [8] Yan HZ, Yu HY, Liu HM, et al. Expression of drug-resistant protein MRP1 and BCRP in breast cancer and its clinical signifi cance[J]. Di Er Jun Yi Da Xue Xue Bao, 2011,32(2):216-9. [颜红柱,余宏宇, 刘会敏,等. 浸润性乳腺癌中耐药基因蛋白MRP1和BCRP 的表 达及临床病理意义[J].第二军医大学学报,2011,32(2):216-9.] [9] Liu XL, Ge J, Chen P, et al. Expression of drug resistance related proteins in breast cancer tissues and its relationship with ER, PR, C- erB -2 and Prognosis[J]. Ningxia Yi Ke Da Xue Xue Bao, 20 11, 33(7): 632-5.[刘新兰,葛建,陈萍,等. 乳腺癌组织中耐药相 关蛋白的表达与雌激素、孕激素及原癌基因和预后关系探讨 [J] 宁夏医科大学学报,2011,33(7): 632-5.] [10] Sun YP, Wang SB, Chen YX. The prognostic signifi cance of breast cancer resistance protein (BCRP) expression in primary breast carcinoma[J]. Zhongguo Ai Zheng Za Zhi,2004,14(2):123-6.[孙 宇萍,王树滨, 陈亦欣,等.乳腺癌耐药蛋白在乳腺癌组织中 的表达及其与预后的关系[J].中国癌症杂志,2004,14(2):123-6.] [11] Zhang GX, Liu XL Li JP. Expressions of MDR1, BCRP and LRP genes in breast cancer tissues and their signifi cance[J]. Xi’an Jiao Tong Da Xue Xue Bao(Yi Xue Ban),2012,33(1):79-83.[张桂香,刘 新兰,李金平. MDR1、BCRP和LRP基因在乳腺癌组织中的表达 及其意义[J]. 西安交通大学学报(医学版),2012,33(1):79-83.]
计量
- 文章访问数: 1114
- HTML全文浏览量: 349
- PDF下载量: 713